Metis TechBio Co., Ltd.
劑泰科技（北京）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 7666)

(1) RESIGNATION OF CHIEF FINANCIAL OFFICER, BOARD SECRETARY AND JOINT COMPANY SECRETARY AND CHANGE OF PROCESS AGENT; (2) CHANGE OF ADMINISTRATIVE POSITIONS

(1) RESIGNATION OF CHIEF FINANCIAL OFFICER, BOARD SECRETARY AND JOINT COMPANY SECRETARY AND CHANGE OF PROCESS AGENT

The board of directors (the "**Board**") of Metis TechBio Co., Ltd. (the "**Company**") hereby announces that due to work changes, Dr. Chong Fu, alias Dr. Alan Fu ("**Dr. Fu**") has resigned as the chief financial officer, Board secretary, joint company secretary and the authorized representative of the Company for service of process and notices in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 19A.13(2) of the Listing Rules (the "**Process Agent**"), with effect from August 1, 2026.

Following the Company's successful completion of its Hong Kong initial public offering and its entry into a new stage of development, Dr. Fu will serve as an advisor to the Company on capital and international development, focusing on providing support and advice to the Company on capital cooperation, international development, establishment of new companies (NewCo), strategic investments and other strategic development matters of the Company.

Dr. Fu joined the Company in 2025 and made significant contributions to the Company's financing and listing during his tenure as chief financial officer. Dr. Fu has confirmed that he has no disagreement with the Board and that there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). The Board would like to take this opportunity to express its sincere gratitude to Dr. Fu for his contributions to the Company during his tenure.

Following Dr. Fu's resignation from the above positions, Ms. Hei Chan, the other joint company secretary of the Company (who possesses the professional qualifications and relevant experience required under Rule 3.28 of the Listing Rules), will remain in office and continue to serve as the company secretary of the Company. She will also be appointed as the Process Agent of the Company with effect from August 1, 2026.

(2) CHANGE OF ADMINISTRATIVE POSITIONS

The Board of the Company hereby announces that, as resolved by the Board, in order to comply with the requirements of the Company Law of the People's Republic of China and other relevant laws and regulations, and to clarify the corporate governance structure, the Company will appoint Mr. Jun Peng ("**Mr. Peng**") as the Board secretary of the Company with effect from August 1, 2026.

Mr. Jun Peng (彭駿), aged 36, holds a master's degree and is a member of the Hong Kong Institute of Certified Public Accountants (HKICPA) with extensive experience in capital operations. Prior to joining the Company, Mr. Peng served as the company secretary and director of investor relations of Phancy Group Co., Ltd. (6682.HK), where he was deeply involved in the company's capital market operations, responsible for investor relations management, corporate governance, regulatory compliance, information disclosure and financing projects, and maintained close communication and cooperation with global institutional investors.

Mr. Peng joined the Company in June 2026 as the head of capital markets, taking overall responsibility for investor relations management, information disclosure, public relations, investment and financing and capital market related matters. He works closely with the management team and the Board to enhance the Company's communication with investors and the capital markets, supports the Company's strategic development and capital operations, and continuously enhances the Company's capital market influence, market recognition and long-term value creation capabilities.

In addition, with effect from August 1, 2026, Ms. Xie Wang ("**Ms. Wang**") has been appointed as the financial controller of the Company, reporting directly to the chief executive officer.

Ms. Xie Wang (王榭), aged 43, holds a master's degree and is a member of the Association of Chartered Certified Accountants (ACCA) and a Chartered Professional Accountant in Canada with extensive experience in financial operations. She has served as the financial director of the Company since joining the Company in 2021. Prior to that, she served as the financial controller in various companies and has over 20 years of experience in financial management, internal audit and treasury management.

The Board would like to take this opportunity to welcome Mr. Peng and Ms. Wang to their new roles.

By Order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai
Chairman of the Board, executive Director and chief executive officer

Hong Kong, July 31, 2026

As of the date of this announcement, the Board comprises Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as independent non-executive Directors.